Platelet integrin $\alpha_6\beta_1$ controls lung metastasis through direct binding to cancer cell–derived ADAM9

Elmina Mammadova-Bach, … , Christian Gachet, Pierre Henri Mangin

*JCI Insight.* 2016;1(14):e88245. [https://doi.org/10.1172/jci.insight.88245](https://doi.org/10.1172/jci.insight.88245).

Metastatic dissemination of cancer cells, which accounts for 90% of cancer mortality, is the ultimate hallmark of malignancy. Growing evidence suggests that blood platelets have a predominant role in tumor metastasis; however, the molecular mechanisms involved remain elusive. Here, we demonstrate that genetic deficiency of integrin $\alpha_6\beta_1$ on platelets markedly decreases experimental and spontaneous lung metastasis. In vitro and in vivo assays reveal that human and mouse platelet $\alpha_6\beta_1$ supports platelet adhesion to various types of cancer cells. Using a knockdown approach, we identified ADAM9 as the major counter receptor of $\alpha_6\beta_1$ on both human and mouse tumor cells. Static and flow-based adhesion assays of platelets binding to DC-9, a recombinant protein covering the disintegrin-cysteine domain of ADAM9, demonstrated that this receptor directly binds to platelet $\alpha_6\beta_1$. In vivo studies showed that the interplay between platelet $\alpha_6\beta_1$ and tumor cell–expressed ADAM9 promotes efficient lung metastasis. The integrin $\alpha_6\beta_1$–dependent platelet-tumor cell interaction induces platelet activation and favors the extravasation process of tumor cells. Finally, we demonstrate that a pharmacological approach targeting $\alpha_6\beta_1$ efficiently impairs tumor metastasis through a platelet-dependent mechanism. Our study reveals a mechanism by which platelets promote tumor metastasis and suggests that integrin $\alpha_6\beta_1$ represents a promising target for antimetastatic therapies.

Find the latest version:

[http://jci.me/88245-pdf](http://jci.me/88245-pdf)
Platelet integrin α6β1 controls lung metastasis through direct binding to cancer cell–derived ADAM9

Elmina Mammadova-Bach,1 Paola Zigrino,2 Camille Brucker,1 Catherine Bourdon,1 Monique Freund,3 Adèle De Arcangelis,4 Scott I. Abrams,4 Gertaud Orend,5 Christian Gachet,1 and Pierre Henri Mangin1

1UMR-S949, INSERM, Etablissement Français du Sang-Alsace, Université de Strasbourg, Strasbourg, France. Fédération de Médecine Translationnelle de Strasbourg, Strasbourg, France. 2Department of Dermatology and Venerology, University of Cologne, Cologne, Germany. 3U964, INSERM, UMR 7104, CNRS, Université de Strasbourg, Institut de Génétique et de Biologie Moléculaire et Cellulaire, Illkirch, Strasbourg, France. 4Department of Immunology, Roswell Park Cancer Institute, Buffalo, New York, USA. 5INSERM U1109, The Microenvironmental Niche in Tumorigenesis and Targeted Therapy, Université de Strasbourg, Fédération de Médecine Translationnelle de Strasbourg, LabEx MedaliS, Strasbourg, France.

Introduction

Metastasis is the leading cause of cancer-related death and represents a major challenge in patient care. To metastasize, a tumor cell must undergo various steps of cancer progression, including detachment from the primary tumor, intravasation into the vascular system directly or through lymph nodes, survival in the circulation, arrest on endothelial cells, and finally extravasation, survival, and proliferation in distant organs (1, 2). Metastasis is a highly inefficient process, as less than 0.1% of tumor cells which penetrate the circulation end up forming metastatic colonies (3, 4). The molecular events driving metastasis, notably those occurring within the bloodstream and related to their physical and functional interaction with circulating blood cells, remain incompletely understood.

Once they enter the bloodstream, tumor cells come in the vicinity of circulating cells and rapidly bind to platelets (5). This physical interaction might allow platelets to participate in the metastatic dissemination by regulating various tumor cell functions (5, 6). Platelets were proposed to form a physical shield around tumor cells protecting them from shear stress and cytotoxic effects of natural killers (7, 8). Moreover, platelets were proposed to promote epithelial-mesenchymal transition of tumor cells through TGF-β and NF-κB signaling, thus promoting tumor metastasis (9). They could also support tumor cell attachment to the endothelium (10–12) and promote their extravasation by increasing endothelial permeability (13).

Tumor cells interact with their environment through a variety of transmembrane proteins, including integrins, selectins, cadherins, and other intercellular adhesion molecules that not only support cell-cell
interactions, but also mediate tumor progression and metastasis (1, 14–16). Concerning platelets, specific surface receptors, such as C-type lectin-like receptor 2 (CLEC-2) (17), and the integrin αIIbβ3 (18–20) mediate interactions between platelets and tumor cells. Platelets also express other integrins, such as αvβ3 and 3 β1-containing integrins, namely α2β1, α5β1, and α6β1. Using mice with a genetic deletion of α6β1 in platelets, we previously reported that this integrin supports platelet adhesion and activation of vascular laminins and promotes experimental thrombus formation, while playing no major role in hemostatic functions (21). To date, the role of the platelet β1 integrins, notably α6β1, in physical and functional interactions with tumor cells and in metastatic dissemination is completely unknown.

Integrin α6β1, which is expressed on cancer and endothelial cells, has been described to favor tumor angiogenesis, invasiveness, and cancer progression (22–27). Besides laminins, this integrin has also been reported to bind ADAM9/meltrin-γ, a member of the a disintegrin and metalloproteinase (ADAM) family of proteins (28, 29). The ADAM family of membrane-anchored proteins contains a number of characteristic domains, including a signal sequence followed by a prodomain, a metalloproteinase domain, a disintegrin-like domain, and a short cytoplasmic tail. Members of the ADAM family have been implicated in a number of important cellular processes, including cell-cell and cell-matrix interactions, cell fusion, and cell signaling (30). Although studies have often focused on the proteolytic activity of members of this family, there is increasing evidence that they play a role in cell adhesion through direct interaction with integrins. ADAM9 is a widely expressed non–Arg-Gly-Asp–containing molecule, which has been shown to bind to αvβ5 on myeloma cells, α3β1 on keratinocytes, and α6β1 on fibroblasts (28, 29, 31–34). These studies raise the possibility that ADAM9 could mediate cell-platelet interactions to regulate dissemination of cancer cells.

The proposed role of platelet adhesion receptors in metastatic dissemination and the involvement of integrin receptors in several hallmarks of tumor cells prompted us to investigate whether platelet integrin α6β1 participates in tumor metastasis. In this study, we demonstrate that platelets promote spontaneous and experimental lung metastasis through an interaction between platelet integrin α6β1 and ADAM9 expressed on tumor cells. Our findings reveal that platelet integrin α6β1 and its counter receptor ADAM9 on tumor cells may represent new therapeutic targets to prevent metastasis.

Results

Genetic deficiency of α6β1 integrin on platelets leads to decreased tumor metastasis in mice. Spontaneous transplant models of metastasis encompass several steps of the tumor process, from primary tumor growth to subsequent metastasis. We used breast cancer cells (AT-3 cells) derived from primary tumors of mammary tumor virus–driven polyoma middle T (MMTV-PyMT) transgenic mice, which, upon orthotopic injection in the mammary fat pad of C57BL/6 mice, developed primary tumors that metastasized into the lungs (Figure 1A). Grafting of these cells led to the growth of mammary tumors with a similar kinetic in platelet-specific PF4-Cre-α6–/– mice as compared with controls (Figure 1, B and C). In contrast, the number of spontaneous lung metastases was reduced by 1.9-fold and 2.1-fold in PF4-Cre-α6–/– and PF4-Cre-β1–/– mice when compared with controls, highlighting a role of platelet α6β1 in tumor metastasis (Figure 1, D–G). This was further confirmed when AT-3 tumor cells were injected directly into the tail vein (Figure 1H), which also resulted in a significant decrease in tumor cell colonization to the lungs in PF4-Cre-α6–/– (Figure 1I) and PF4-Cre-β1–/– (Figure 1J) mice when compared with controls. Moreover, similar results were obtained in 3 distinct experimental metastasis models based on i.v. injection of B16F10 melanoma cells (Figure 1, H, K, and L), MC38 colon carcinoma cells (Supplemental Figure 1A; supplemental material available online with this article; doi:10.1172/jci.insight.88245DS1), and E0771 medullary mammary adenocarcinoma cells (Supplemental Figure 1B), all of which resulted in a marked reduction in pulmonary metastases in PF4-Cre-α6–/– mice as compared with controls. Collectively, these data support a major role for platelet integrin α6β1 in tumor metastasis.

Integrin α6β1 mediates direct interaction of platelets with tumor cells. Distant metastases mainly occur through hematogenous dissemination via the blood circulation, and platelets were proposed to be the first blood cells to interact with tumor cells (5). To determine whether integrin α6β1 supports platelet-tumor cell interaction, washed fluorescently labeled platelets were allowed to adhere to tumor cells under static conditions. As shown in Figure 2, A and B, deficiency of α6β1 resulted in a 2.6-, 2.8-, and 1.5-fold reduction in washed mouse platelet recruitment to AT-3 breast cancer, MC38 colon carcinoma, and B16F10 melanoma cells as compared with controls. Similar results were obtained with washed human platelets in which the α6-blocking antibody, GoH3, reduced platelet adhesion to human breast and colon cancer cells (MDA-MB-231,
Figure 1. Lack of platelet integrin α6β1 inhibits tumor metastasis. (A) Schematic of a mouse orthotopic metastasis assay. AT-3 tumor cells were injected into the fourth mammary fat pad of PF4-Cre-α6+/+, PF4-Cre-β1+/+, and control mice, and the volume of primary tumor in the mammary fat pad and the number of lung metastasis were determined. (B and C) Kinetic of primary tumor growth in (B) PF4-Cre-α6+/+ and PF4-Cre-α6+/− mice and (C) PF4-Cre and PF4-Cre-β1+/− mice. Six mice per each group were used. Error bars represent S.E.M. (D and F) Representative H&E-stained sections
obtained from lungs of AT-3–injected (D) PF4-Cre-α6<sup>+/−</sup> and PF4-Cre-α6<sup>−/−</sup> and (F) PF4-Cre and PF4-Cre-β<sup>+/−</sup> mice. Black arrows indicate metastatic nodules. Scale bar: 200 μm. (H) Schematic of a lung colonization assay following i.v. injection of (I) AT-3 or (K and L) B16F10 tumor cells in indicated mice. Numbers of metastatic foci in lung tissues of AT-3–injected (E and I) PF4-Cre-α6<sup>−/−</sup> and PF4-Cre-α6<sup>+/−</sup> mice and (G and J) PF4-Cre and PF4-Cre-β<sup>+/−</sup> mice. *P < 0.05, **P < 0.01, Mann-Whitney test. (K) Representative photographs obtained from lungs of B16F10-injected PF4-Cre-α6<sup>−/−</sup> and PF4-Cre-α6<sup>+/−</sup> mice. (L) Numbers of metastatic nodules on the surface of B16F10-injected PF4-Cre-α6<sup>−/−</sup> and PF4-Cre-α6<sup>+/−</sup> mice. **P < 0.01, Student’s t test. (E, G, I, J, and L) Each point represents an individual mouse. Box-and-whisker plots were used to graphically represent the median (line within box), upper and lower quartile (bounds of box), and maximum and minimum values (bars).
Figure 2. Platelet integrin α6β1 deficiency or blockade impairs platelet and tumor cell interaction. Platelet adhesion to tumor cells was quantified based on the fluorescence detection of RAM.1-labeled platelets, as described in Methods. (A) Representative epifluorescence microcopy images of RAM.1-Alexa 488-labeled mouse PF4-Cre-α6+/+ and PF4-Cre-α6–/– platelets (green) adhering to AT-3 tumor cells. Scale bar: 50 μm. (B and C) Quantification of the fluorescent signal corresponding to the amount of platelets allowed to adhere to tumor cells. (B) Washed PF4-Cre-α6+/+ or PF4-Cre-α6–/– mouse platelets were allowed to adhere on AT-3 breast cancer, MC38 colon carcinoma, and B16F10 melanoma cells. (C) Washed human platelets were treated with an irrelevant IgG (control) or blocking antibodies against α6 (GoH3) or β1 (P5D2) integrin (10 μg/ml) and cultured on MDA-MB-231, SKRB-3 breast, and LoVo colon cancer cells. *P < 0.05, **P < 0.01, ***P < 0.001, Mann-Whitney test. (D) Experimental design. c-mpl–/– mice were injected with
led to an approximately 2-fold reduction in the number of lung metastases compared with control cells (Figure 4B). ADAM9 knockdown caused a similar impairment in lung colonization of AT-3 or MC38 tumor cells following inoculation via the tail vein (Figure 4, C and D). Of note, in both experimental and spontaneous lung metastasis models, ADAM9 deficiency did not cause an additional decrease in lung metastasis in PF4-Cre-α6–/– mice, and no further inhibition was achieved when both α6β1 and ADAM9 were lacking, suggesting that the α6β1-ADAM9 interplay mediates metastasis (Figure 4, B–D). To provide further evidence, PF4-Cre-α6+/+ and PF4-Cre-α6–/– washed platelets were transfused into PF4-Cre-α6–/– mice together with control or AT-3–deficient ADAM9 cells (Figure 4E). As shown in Figure 4E, transfusion of WT, but not α6β1-deficient, platelets partially rescued AT-3 cell–induced metastasis in PF4-Cre-α6–/– mice. In contrast, transfusion of WT platelets failed to restore metastasis when ADAM9-deficient AT-3 cells were injected into PF4-Cre-α6–/– mice (Figure 4E). Thus, our results suggest that platelet α6β1 integrin enhances lung metastasis through direct interaction with ADAM9 expressed on tumor cells.

Platelet α6β1 binding to tumor cell ADAM9 promotes platelet activation, granule secretion, and tumor cell extravasation. To get insight into the mechanism by which platelet α6β1 promotes metastasis through an interplay with ADAM9, we evaluated the impact of its absence on DC9-mediated platelet activation. We found that deficiency of α6β1 significantly decreased DC9–induced filopodia extension of adherent platelets (Figure 5, A and B). We also observed that PF4-Cre-α6–/– platelets adherent to DC-9 presented a significant reduction of P-selectin exposure, a recognized marker of α-granule secretion, when compared with controls (Figure 5, C and D). In agreement, we could show that PF4-Cre-α6–/– platelets adherent to AT-3 tumor cells, exposed less P-selectin at their surface, suggesting that α6β1 is involved in tumor cell–induced platelet activation (Figure 5, E and F). Altogether, these results suggest that direct interaction of α6β1 with ADAM9 promotes platelet activation and granule secretion. Recent studies reported that tumor cell–activated platelets promote extravasation of circulating tumor cells, thereby enhancing their metastatic potential (13). Thus, we hypothesized that the interplay between platelet integrin α6β1 and ADAM9 could favor tumor cell extravasation. To evaluate this hypothesis, control and ADAM9-silenced AT-3 cells were allowed to migrate through an endothelial cell layer–coated Transwell insert alone or in presence of PF4-Cre-α6+/+ or PF4-Cre-α6–/– platelets. We first observed that addition of washed WT platelets enhanced transendothelial migration of AT-3 cells by 2.7-fold compared with controls (Figure 5G). In contrast, combining PF4-Cre-α6+/+ platelets with control tumor cells, or PF4-Cre-α6–/– platelets with ADAM9-deficient AT-3 cells, failed to increase transendothelial migration (Figure 5G). This result suggests that the interplay between platelet integrin α6β1 and ADAM9 favors tumor cell extravasation in vitro. To determine whether platelet integrin α6β1 has a similar effect in vivo, CFSE-labeled AT-3 cells were i.v. injected into PF4-Cre-α6+/+ and PF4-Cre-α6–/– mice. While the number of tumor cells present in the lungs was normal 6 hours after injection (Supplemental Figure 6), a smaller proportion of them were localized in the extravascular compartment in PF4-Cre-α6–/– mice compared with controls (Figure 5, H and I). Collectively, these data suggest that platelet α6β1 and tumor ADAM9 cooperate to promote platelet activation and granule secretion and to ensure efficient tumor cell extravasation, thereby promoting tumor metastasis.

Pharmacological targeting of integrin α6β1 reduces tumor metastasis. To explore the antimitastatic potential of a pharmacological strategy aiming to target α6β1 integrin (Figure 6A), mice inoculated with AT-3 (Figure 6B) or B16F10 (Figure 6, C and D) tumor cells were treated by tail vein injection together with a control or the anti-α6–blocking antibody GoH3. We first demonstrated that administration of 2 mg/kg of GoH3 did not induce a thrombocytopenia (Figure 6A) and had no impact on the level of circulating red blood cells, white blood cells, and hemoglobin (Supplemental Figure 7). Importantly, GoH3 treatment efficiently inhibited lung metastasis mediated by both tumor cell lines in control mice (Figure 6, B and C). Its specificity is evidenced by the finding that GoH3 displayed no effect in PF4-Cre-α6–/– mice (Figure 6, B and C). Interestingly, administration of GoH3 at day 5 after injection of tumor cells did not inhibit anymore tumor
metastasis, suggesting that this integrin plays a role in early stages of the metastatic process (Figure 6D). These data further confirmed the requirement of platelet integrin α6β1 for efficient metastasis and suggest that blockade of this receptor may represent a powerful strategy to prevent tumor cell dissemination at early stages of metastasis.

Discussion

Over the last few decades, although numerous potential mechanisms through which platelets mediate tumor metastasis were proposed, the molecular events driving direct platelet-tumor cell interplay still remain incompletely understood. In the present report, by employing a megakaryocyte-restricted knockout strategy, we highlighted a major role for integrin α6β1 in supporting direct platelet binding to tumor cells. We identified ADAM9 as being the counter receptor of platelet α6β1 on tumor cells. We also provided evidence that the interaction of α6β1 with ADAM9 promotes platelet activation and subsequent tumor cell extravasation, thereby favoring lung metastasis associated notably to breast cancer.

A major highlight of our study relies on the identification of an important contribution of platelet integrin α6β1 to tumor metastasis. Evidence was derived, not only from a pharmacological approach based on a blocking anti–integrin α6 antibody, but also from mice that were specifically knocked out for integrin α6 in the megakaryocytic lineage. Moreover, we showed that transfusion of WT, but not α6-deficient, platelets partially restored metastasis in both thrombocytopenic and PPF4-Cre-α6–/– mice, confirming that the protective effect is platelet specific and does not rely on the absence of α6β1 integrin on any other cell type. In addition, we previously reported that platelets from PPF4-Cre-α6–/– mice expressed normal levels of the main adhesion receptors (21), further pointing towards a specific role for α6β1. Blood platelets express two additional members of the β1 integrin family, namely α2β1 and α5β1. Whether one of these two platelet β1 integrins also participates in metastasis remains unknown. Although it might be tempting to speculate that neither of them is critical, since the reduction of tumor metastasis in PPF4-Cre-α6–/– mice was very similar to that in PPF4-Cre-β1–/– animals, future studies are warranted to investigate this issue in detail.

Our results point to a prometastatic function of ADAM9 expressed on breast and colon cancer cells in an immunocompetent mouse model. These observations are in line with a previous study in which downregulation of ADAM9 in cystic carcinoma cells led to less lung metastasis, as determined by i.v. injection into nude mice (36). In agreement, overexpression of ADAM9 in lung cancer cells resulted in both brain and lung metastases, whereas mock-transfected cells only colonized the lungs (37, 38). All these results are in accordance with clinical observations indicating that expression of ADAM9 was correlated with shortened survival and poor outcome of cancer patients and associated with the occurrence of distant metastases (39–41). ADAM9 was reported to be expressed by several malignancies, including renal, prostate, thyroid, gastric, breast, and non–small-cell lung cancer cells, highlighting its potentially broader importance in neoplasia (38, 39, 42–46). Moreover, ADAM9 overexpression was shown to be associated with poor differentiation, tumor aggressiveness, and shortened survival in patients with pancreatic tumors (47). Nevertheless, suggesting that ADAM9 might represent an attractive target for numerous cancers appears premature, since ablation of ADAM9 in tumor-associated fibroblasts has been reported to enhance tumor growth (48). Therefore, questions around the cell-specific function of ADAM9 in metastasis still need to be fully elucidated.
βADAM9 on tumor cells mediates lung metastasis through platelet integrin α1. sh control and sh ADAM9 tumor cells (sh1 and sh2) were injected into (A and B) the mammary fat pad region (AT-3 cells) or (C-E) directly in tail veins (AT-3 or MC38) of PF4-Cre-α6+/+ and PF4-Cre-α6–/– mice. (E) PF4-Cre-α6+/+ and PF4-Cre-α6–/– mice were transfused with PF4-Cre-α6+/+ and PF4-Cre-α6–/– platelets and injected collaterally with AT-3 cells (sh ctrl or sh1 ADAM9). (A) Volumes of primary tumors (AT-3) were determined at the indicated days after tumor cell injection. Six mice per each group were used. (B) Spontaneous and (C-E) experimental lung metastasis were determined at 30 (AT-3) or 20 (AT-3 or MC38) days of after injection, respectively. Quantification of (A) mammary tumor volume and (B-E) metastatic foci in lung sections of PF4-Cre-α6+/+ and PF4-Cre-α6–/– mice. *P < 0.05, **P < 0.01, Mann-Whitney test. Each point represents an individual mouse. (B-E) Box-and-whisker plots were used to graphically represent the median (line within box), upper and lower quartile (bounds of box), and maximum and minimum values (bars).

Our results identified α6β1 as a receptor supporting efficient adhesion of platelets to tumor cells through direct interaction with ADAM9. We also demonstrated that this molecular interaction led to platelet activation, as evidenced by a defective platelet shape change on DC-9 when α6β1 is absent. This result demonstrates that ADAM9 is able to initiate an intraplatelet signal downstream of α6β1. Whether this signaling is similar to that initiated by the typical α6β1 ligands, laminins, requires further detailed investigation. ADAM9-induced signals result not only in a platelet shape change, but also in P-selectin exposure, indicating that granule secretion occurs. Platelet granules contain many bioactive molecules, including TGF-β and ADP and ATP, which were previously described to modulate directly or indirectly the metastatic potential of tumor cells (9, 13, 49). Platelet release of TGF-β is a well-accepted event by which platelets enhance the invasiveness of tumor cells notably by promoting epithelial-to-mesenchymal transition (9). Besides, ATP secreted from activated platelets was reported to bind the endothelial P2Y1 receptor, promoting vascular permeability and thereby facilitating tumor cell extravasation (13). Altogether, we propose a working model, whereby platelet α6β1 binding to ADAM9 on tumor cells promotes platelet activation and the subsequent secretion of the granule contents. The bioactive molecules released by activated platelets could in turn promote tumor cell extravasation either indirectly by inducing vascular permeability or directly by promoting tumor cell invasiveness, ultimately leading to metastasis of distant organs (Figure 7).

We provided evidence that i.v. injection of GoH3, an integrin α6-blocking antibody that prevents platelet-tumor cell crosstalk, diminished lung metastasis in WT mice. This observation opens up the intriguing possibility of developing a therapeutic strategy aimed at targeting this integrin to interfere with tumor cell dissemination in cancer patients. Of note, this blocking antibody did not provoke a thrombocytopenia, suggesting that such a pharmacological approach would preserve a normal platelet count. In addition, since platelet integrin α6β1 appears dispensable for normal hemostasis (21), one could hypothesize that targeting this integrin would also avoid bleeding complications. This is of importance since currently used antiplatelet drugs are known to increase the bleeding risk that complicates their use in clinical settings (50–53). Besides, the specificity of pharmacologically targeting platelet α6β1 was evidenced by the loss of protective effect when GoH3 was administrated to PF4-Cre-α6–/– mice. This observation suggests that such an approach would primarily act through α6β1 expressed on platelets to prevent metastasis. Preclinical studies are necessary to identify the stage at which such a therapeutic approach would confer an optimal antitumorigenic effect as well as potential side effects due to long-term treatment. It has been reported that defects in α6 integrin result in hemidesmosome deficiency and cause skin and mucous membrane disorders, such as pyloric atresia and epidermolysis bullosa, and, in most cases, early postnatal death (54, 55). Whether a pharmacological strategy would result in such pathologies occurring during development is uncertain but will need to be tested. Future studies might also highlight a potential net benefit of targeting other cellular pools of this integrin, since some of them, notably those expressed on endothelial or tumor cells, also actively participate in cancer progression (22–27).

In conclusion, our study reveals a major contribution of integrin α6β1 to platelet interaction with tumor cells through the binding of ADAM9. This interaction promotes platelet activation, granule secretion, and subsequent endothelial transmigration of tumor cells, ultimately promoting tumor metastasis. Finally, we propose that targeting α6β1 may offer a potentially interesting antitumorigenic strategy to be used in conjunction with traditional strategies.

**Methods**

*Animals.* C57BL/6 mice were obtained from Charles River Laboratories. PF4-Cre and c-mpl–/– mice were provided by Radek Skoda (Experimental Hematology, University Hospital Basel, Basel, Switzerland). PF4-Cre-α6–/– and their littermate control PF4-Cre-α6+/+ mice were generated as previously described (21). To generate mice lacking integrin β1 in platelets, C57BL/6 mice containing the Igβ1 gene flanked by loxP...
sites, β1<sup>6–/+</sup> were crossed with PF4-Cre mice (provided by Reinhard Fässler, Max Planck Institute of Biochemistry, Martinsried, Germany). All experiments with animals were performed in accordance with French legislation and INSERM guidelines and followed the recommendations of the Guide for the Care and Use of Laboratory Animals (National Academies Press. 2011).

Cell culture. Cell lines were cultured in a humidified incubator with 5% CO<sub>2</sub> at 37°C. The PyMT cells, termed AT-3 cells, were isolated from a mammary carcinoma of MMTV-PyMT transgenic mice in a C57BL/6 background, as previously described (56). AT-3, B16-F10 (mouse melanoma, ATCC CRL-6475), MDA-MB-231 (human breast carcinoma, ATCC HTB-26), SKRB3 (human breast carcinoma, ATCC HTB-30), and LoVo (colon carcinoma, ATCC CCL-229) cells were maintained in DMEM (CliniSciences). E0771 mouse medullary mammary adenocarcinoma (tebu-bio) and MC38 mouse colon carcinoma (provided by Pedro Berrando Lopez, University of Navarra, Pamplona, Spain) cell lines were cultured in RPMI 1640 medium (CliniSciences). All media were supplemented with fetal bovine serum (Biowest) 10%, penicillin-streptomycin (Life Technologies) control. Primer sequences are listed in Supplemental Table 1.

Establishment of ADAM9 knockdown cells. Human embryonic kidney 293T (HEK293T) cells were transfected with pGFP-C sh human ADAM9 (sh1: TL314947A CTTGCTGCGAAGGAAGTACCTGTAAGCTT) lentiviral vector, pGFP-C sh mouse ADAM9 (sh1: TL500040B CAAACGTACAGAGCCATTGTAACAGCAATAAGAATTGTCACT) lentiviral vector, or pGFP-C short hairpin RNA control (sh ctrl) lentiviral vector (TR30021) containing a noneffective 29-mer scrambled shRNA cassette (OriGene, CliniSciences) together with pLP1, pLP2, and pLP/VSVG vectors (Life Technologies) to obtain lentiviral particles. After 48 hours, conditioned media from HEK293T cells were collected, centrifuged to remove cell debris, and used to transduce AT-3, MC-38, and MDA-MB-231 cells in the presence of 5 μg/ml polybrene (Sigma-Aldrich), followed by selection with puromycin (1.5–2 μg/ml) (Sigma-Aldrich). Expression of ADAM9 was determined by quantitative real-time PCR (qRT-PCR) and immunofluorescence staining.

qRT-PCR. Total RNA from cell lines or mouse lungs was extracted with TriReagent according to the manufacturer’s instructions (Life Technologies). RNA was treated with DNaseI and reverse transcribed using the High-Capacity cDNA RT Kit (Life Technologies). qRT-PCR was performed using the Power SYBR Green PCR Master Mix (Life Technologies) according to the manufacturer’s protocol. Relative values of gene expression were normalized to GAPDH, and fold change in relative expression was determined by calculating 2<sup>−ΔΔCt</sup>, where ΔΔCt = (ΔCt target gene − ΔCt GAPDH) sample − (ΔCt target gene − ΔCt GAPDH) control. Primer sequences are listed in Supplemental Table 1.

Expression and purification of DC-9. Recombinant DC-9 was produced as previously described (33). Briefly, HEK293-EBNA cells were transfected by JetPei (Polyplus) with pCEP-pu BM40-cHis-Dis-Cys plasmid giving rise to a fusion protein with a His<sub>6</sub> tag placed in frame with disintegrin-cysteine-rich coding regions of ADAM9. Then, supernatants were collected and proteins were purified by metal affinity chromatographic columns (CliniSciences).

Experimental and spontaneous models of metastasis. For experimental metastasis models, 3 × 10<sup>5</sup> B16F10, E0771, AT-3, and MC38 parental cells or sh ctrl or sh ADAM9 clones in 200 μl of cell media were injected into a lateral tail vein of each mouse. Mice were sacrificed on day 20 after tumor cell inoculation, and the
The number of metastases was determined by counting metastatic foci on the lung surface (B16F10 model) and histopathological analysis (as described below). For orthotopic breast cancer models, $2 \times 10^5$ parental AT-3 or AT-3 sh ctrl and AT-3 sh ADAM9 cells were injected into the mammary fat pads of 8-week-old female virgin mice, which were sacrificed on day 30. Primary tumor volumes were measured using Vernier calipers and determined using following calculation: $\text{volume} = \frac{(\text{width})^2 \times \text{length}}{2}$.

H&E staining. Lung tissues were collected and fixed in 4% PFA and then dehydrated in sucrose 20% and embedded in OCT medium and cross sectioned (7 μm). Tissue sections were stained with hematoxylin for 5 minutes and washed with running tap water. Differentiation was accomplished in acid alcohol for 10 seconds followed by washing for 10 minutes. Tissues sections were incubated in eosin for 20 seconds, rinsed, and mounted using the Savemount reagent (vwr chemicals, BDH Prolabo). Stained tissues were observed under a light microscope (Zeiss Imager Z2 inverted microscope and AxioVision software, Carl Zeiss), and metastases were counted by two separate experimenters.

Figure 6. Antibody-mediated blockade of $\alpha_6\beta_1$ integrin inhibits tumor metastasis. (A) Effect of the injection of GoH3, an $\alpha_6$-blocking antibody, on platelet count. C57BL/6 mice were injected with 2 mg/kg GoH3 or irrelevant control IgG, and 15, 30, and 60 minutes later the platelet count was determined. Horizontal black bars denote the mean. Mean ± SEM. (B–D) PF4-Cre-α$6^{+/+}$ and PF4-Cre-α$6^{−/−}$ mice were i.v. injected with GoH3 or a control antibody in parallel with indicated tumor cells at indicated times. Numbers of metastatic foci in lung tissues of (B) AT-3–injected or (C and D) B16F10–injected PF4-Cre-α$6^{+/+}$ and PF4-Cre-α$6^{−/−}$ mice. *P < 0.05, **P < 0.01, Mann-Whitney test. Each point represents an individual mouse. (B–D) Box-and-whisker plots were used to graphically represent the median (line within box), upper and lower quartile (bounds of box), and maximum and minimum values (bars).
Blood counts. C57BL/6 mice were injected with α6-blocking antibody (2 mg/kg, GoH3, Santa Cruz Biotechnology) or irrelevant control IgG (2 mg/kg, BD Biosciences). Blood samples were collected from individual mice, and the mouse blood cell count was analyzed using ABC Vet analyzer (SCIL).

Preparation of washed platelets. Blood was drawn from the abdominal aorta of adult mice anesthetized intraperitoneally with a mixture of xylazine (20 mg/kg, Rompun, Bayer) and ketamine (100 mg/kg, Imalgene 1,000, Merial). Human blood was collected from healthy volunteers who had not taken any antiplatelet medication in the preceding 2 weeks. Platelets were washed using ACD-anticoagulated whole blood as previously described (57).

Platelet transfusion. 1 × 10⁹ washed mouse (PF4-Cre-α6+/+ or PF4-Cre-α6–/–) platelets in Tyrode's buffer were injected i.v. into indicated mice via a lateral tail vein.

In vitro platelet adhesion assay. Murine (parental, sh ctrl or sh ADAM9 AT-3, and MC38) or human (parental MDA-MB-231, sh ctrl MDA-MB-231, sh ADAM9 MDA-MB-231, and SKRB3, LoVo) tumor cell lines were seeded into LabTek chamber slides (Labtek) at a concentration of 3 × 10⁵ per well. Washed murine (PF4-Cre-α6+/+ or PF4-Cre-α6–/–) or human platelets incubated with antibodies directed against integrin α6 (GoH3, Santa Cruz Biotechnology) and integrin β1 (P5D2, Santa Cruz Biotechnology) were allowed to adhere to murine or human tumor cells for 15 minutes. To assess activation of platelets the time of experiment was prolonged up to 30 minutes at 37°C. After washing with PBS 1×, chambers were fixed in PFA 4% for 20 minutes and then washed with PBS 1× and incubated overnight with an antibody against P-selectin (1 μg/ml, CLB-Thromb/6, Beckman Coulter). The next day, chambers were incubated for 1 hour with Cy-3-conjugated goat anti-rabbit IgG (1 μg/ml, Jackson ImmunoResearch Laboratories) and stained with Alexa 488–coupled RAM.1 antibody (5 μg/ml) (58). Chambers were mounted and 5 pictures were taken for each condition. Quantification of immunofluorescence signals was obtained using ImageJ software (NIH) and the analyze particle module.

Immunofluorescence staining. AT-3 sh ctrl or sh ADAM9 cells were labeled for 15 minutes at 37°C with 10 μg/ml CFSE (Life Technologies) in serum-free medium and washed twice with PBS 1×, and 1 × 10⁶ cells
were i.v. injected into the tail veins of c-mpl−/−, PF4-Cre-a6+/+, or PF4-Cre-a6−/− mice. In some experiments, the mice were i.v. injected with DyLight 594–Lycopersicon esculentum (Tomato) lectin (100 μl per mouse) 30 minutes, 2 hours, 4 hours, and 6 hours later. After 10 minutes, lungs were collected as described above and cryosectioned (10 μm) for fluorescence imaging to visualize the vasculature (red) and tumor cells (green). For platelet immunostaining in lungs, 7-μm-thick sections were incubated for 1 hour with Cy-3–conjugated RAM.1 antibody (5 μg/ml). For immunostaining in cell cultures, B16F10, E0771, MDA-MB-231, SKBR3, LoVo, AT-3 sh ctrl or sh ADAM9 cells, and MC38 sh ctrl or sh ADAM9 tumor cells were fixed with PFA 4% in PBS 1× for 15 minutes, washed and blocked in PBS 1× 5% normal goat serum, followed by a staining with the primary antibody against ADAM9 (0.5 μg/ml AB2959, Chemicon, Millipore). After washing, cells were incubated for 1 hour with Cy-3–conjugated goat anti-rabbit IgG (1 μg/ml, Jackson ImmunoResearch Laboratories). Tissue sections and cell cultures were counterstained with DAPI (1:36,000), mounted using the FluorSave reagent (Calbiochem), and observed with an epifluorescence microscope (Leica Microsystems) and ×63 oil immersion objective. Tumor cells overlapping with vasculature were scored as intravascular, while cells outside blood vessels were scored as extravascular.

Static adhesion assay. Glass coverslips were coated with recombinant DC-9 (500 μg/ml) for 2 hours at room temperature and blocked with human serum albumin (HSA) 1% in PBS 1× for 60 minutes. PF4-Cre-a6+/+ and PF4-Cre-a6−/− mouse platelets (4.5 × 10⁶/coverslip) in Tyrode’s buffer were allowed to adhere to the coated surfaces at 37°C. After 1 hour, nonadherent platelets were washed away and adherent cells were fixed with PFA 4% in PBS 1× and then stained with Alexa 488–conjugated RAM.1 (5 μg/ml) and P-selectin antibody (1 μg/ml, CLB-Thromb/6, Beckman Coulter). Coverslips were mounted and then observed with epifluorescence microscopy (Leica Microsystems) and ×40× and ×100 oil immersion objectives. Ten pictures were taken per each condition, and platelet adhesion was calculated using ImageJ software.

Flow-mediated platelet adhesion. Adhesion assays in a flow system were performed as previously described (59). Microcapillaries were coated with recombinant DC-9 (500 μg/ml) and passivated with 1% HSA 1% in PBS 1× for 30 minutes at room temperature. Hirudin (100 U/ml, Transgene) PF4-Cre-a6+/+ and PF4-Cre-a6−/− mouse whole blood was perfused through the microcapillaries for 3 minutes, at 300 s−1, using a programmable syringe pump (PHD 2000, Harvard Apparatus). Platelet adhesion was observed with a Leica DMI 4000 B (Leica Microsystems) using a ×63, 1.4 numerical aperture oil objective and differential interference contrast microscopy, equipped with a CCD CoolSNAP HQ Monochrome camera (Photometrics). Platelet adhesion was analyzed using Metamorph software version 7.6 (Molecular Devices).

Scanning electron microscopic analysis of the morphological changes of platelets after adhesion to DC-9. Hirudinated (100 U/ml) mouse whole blood was perfused through glass microcapillaries coated with recombinant DC-9 (500 μg/ml) for 3 minutes, at 300 s−1, followed by washing with PBS 1× at 300 s−1. Scanning electron microscopy was performed as described elsewhere (60). Change in cell shape was defined as the transformation of a resting discoid platelet into an activated spherical cell with filopodial projections of more than 0.2 μm in length.

Transwell assay. HUVECs (50,000 at seeding in 50 μl) were cultured for 2 days on 96-well Transwell plates with a 8-μm pore size polyester membrane (Sigma-Aldrich) with medium changes every day. Media from the upper compartment were removed and 50 μl of CFSE-labeled AT-3 sh ctrl or AT-3 sh ADAM9 tumor cells (8 × 10⁶/ml) in Tyrode’s buffer alone or together with a 1:1 mixture of platelets (2 × 10⁹/ml) was added to the upper compartment. In all experiments, 250 μl Tyrode’s buffer or culture media was added to the lower compartment and tumor cells were allowed to transmigrate overnight. On the next day, the nontransmigrated tumor cells from the upper compartment were removed, and only the transmigrated tumor cells on the lower side of the filter or the bottom of the Transwell insert were imaged with an epifluorescence microscope (Leica Microsystems) and quantified with ImageJ. Each experiment was performed 4 times with 5 wells per condition.

Statistics. The statistical significance of results was analyzed using the GraphPad Prism program, version 5.0. The Shapiro-Wilk normality test was used to confirm the normality of the data, and the statistical difference of the mean was analyzed using the Student’s unpaired 2-tailed t test. For data not following a Gaussian distribution, the nonparametric Mann-Whitney test was used. Contingency was analyzed using the Fisher’s exact test. P values of less than 0.05 were considered to be significant.

Study approval. Murine experiments were performed according to French regulations and were approved by the Regional Ethical Committee for Animal Experimentation of Strasbourg (C.R.E.M.E.A.S., CEEA 35) (approval no. for animal experiments: 2015082714213372).
Author contributions
EMB conceived and designed the research, acquired and analyzed the data, and wrote the manuscript. C Brucker, C Bourdon, and MF acquired and analyzed the data. PZ, ADA, SIA, and GO provided essential tools and contributed to the writing of manuscript. CG interpreted the data, contributed to the writing of manuscript, and acquired the funding. PHM conceived and designed the research, interpreted the data, cowrote the manuscript, and acquired the funding.

Acknowledgments
The authors would like to thank Catherine Ziesell, Jean-Yves Rinckel, Sebastien Egard, and Nicolas Receveur (UMR-S949, INSERM, Etablissement Français du Sang-Alsace) for technical assistance and Pedro Berraondo Lopez for MC38 cells (University of Navarra, Spain). This work was supported by INSERM, Etablissement Français du Sang, Association de Recherche et Développement en Médecine et Santé Publique, and Institut National du Cancer (grant no. PLBIO13-079).

Address correspondence to: Pierre Henri Mangin, UMR-S949, INSERM, Université de Strasbourg, Etablissement Français du Sang-Alsace (EFS-Alsace), 10 rue Spielmann, BP no. 36, 67065 Strasbourg Cedex, France. Phone: 33.38.21.25.25; E-mail: pierre.mangin@efs.sante.fr.

Reference


